India’s first COVID-19 vaccine to begin human trails
Drug Controller General of India (DGCI), the country’s top drug regulator has given permission to Bharat Biotech India to conduct human clinical trials or first indigenous COVID-19 vaccine COVAXIN.
The Phase I and Phase II clinical trials of the vaccine for SARS-CoV-2, approved after pre-clinical studies demonstrated safety and immune response, would start across the country in July, a PTI report said.
Chairman and Managing Director of the company Dr. Krishna Ella said: We are proud to announce COVAXIN, Indias first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine.
Also read: COVID-19: ICMR invites Govt, Pvt Medical Colleges to set up testing labs
“The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform,” he said.
The vaccine has been developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). It has been developed at Bharat Biotech’s BSL-3 (Bio-Safety Level 3) high containment facility located in the Genome Valley in Hyderabad.
At a time when Corona virus has created, causing death of millions of people, countries across the globe are trying all possible ways to come up with vaccine for COVID-19. Though many companies have achieved positive results, the vaccine is yet to see the light of the day.
post_id:uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
